Literature DB >> 22314198

Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease.

Guillaume Jean1, Jean-Claude Souberbielle, Eric Zaoui, Christie Lorriaux, Brice Mayor, Jean-Marc Hurot, Patrick Deleaval, Charles Chazot.   

Abstract

OBJECTIVE: The Kidney Disease: Improving Global Outcomes "KDIGO" recommends regular sampling of bone turnover markers (BTMs) such as total alkaline phosphatases (t-ALP) and bone-specific alkaline phosphatase (b-ALP) in the case of haemodialysis (HD) patients. DESIGN AND METHODS: We present our results of the regular assessment of t-ALP, b-ALP, and PTH, obtained for existing HD patients with chronic liver disease (LD).
RESULTS: 76 prevalent HD patients were examined. Linear regression showed that b-ALP and t-ALP levels were closely related (r²: 0.6; p<0.0001), even when the serum PTH level was <250 pg/mL (r²: 0.56; p<0.001). The b-ALP/t-ALP ratio was 0.07 ± 0.12 and correlated poorly with PTH levels (r²: 0.03; p=0.01). Both b-ALP and t-ALP levels did not correlated with PTH levels.
CONCLUSION: Our results did not confirm the KDIGO recommendation for using b-ALP as BTM in the special cases of HD patients with LDs.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314198     DOI: 10.1016/j.clinbiochem.2012.01.018

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis.

Authors:  Annelie Bergman; Abdul Rashid Qureshi; Mathias Haarhaus; Bengt Lindholm; Peter Barany; Olof Heimburger; Peter Stenvinkel; Björn Anderstam
Journal:  J Nephrol       Date:  2016-03-18       Impact factor: 3.902

Review 2.  Rethinking Bone Disease in Kidney Disease.

Authors:  Matthew J Damasiewicz; Thomas L Nickolas
Journal:  JBMR Plus       Date:  2018-11-15

3.  Alkaline phosphatase is a predictor of Bone Mineral Density in postmenopausal females.

Authors:  Sundus Tariq; Saba Tariq; Khalid Parvez Lone; Saba Khaliq
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

4.  Determinants of bone mineral density in patients on haemodialysis or peritoneal dialysis--a cross-sectional, longitudinal study.

Authors:  Mads Nybo; Bente Jespersen; Michael Aarup; Charlotte Ejersted; Anne Pernille Hermann; Kim Brixen
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

5.  Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients.

Authors:  Pierre Delanaye; Xavier Warling; Martial Moonen; Nicole Smelten; François Jouret; Jean-Marie Krzesinski; Nicolas Maillard; Hans Pottel; Etienne Cavalier
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

6.  Different Effects of Empagliflozin on Markers of Mineral-Bone Metabolism in Diabetic and Non-Diabetic Patients with Stage 3 Chronic Kidney Disease.

Authors:  Anna Masajtis-Zagajewska; Tomasz Hołub; Katarzyna Pęczek; Agnieszka Makówka; Michał Nowicki
Journal:  Medicina (Kaunas)       Date:  2021-12-11       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.